Ticker Details
Ultragenyx Pharmaceutical Inc. Ultragenyx Pharmaceutical Inc is biopharmaceutical company. It is engaged identification, acquisition, development and commercialization of novel products for treatment of rare & ultra-rare diseases, with a focus on debilitating genetic diseases.
IPO Date:	January 31, 2014
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$2.19B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$1.55 | 2.50%
Avg Daily Range (30 D):	$0.57 | 2.47%
Avg Daily Range (90 D):	$0.69 | 2.46%

Institutional Daily Volume
Avg Daily Volume:	.55M
Avg Daily Volume (30 D):	2.11M
Avg Daily Volume (90 D):	1.92M

Trade Size
Avg Trade Size (Sh.):	67
Avg Trade Size (Sh.) (30 D):	71
Avg Trade Size (Sh.) (90 D):	68

Institutional Trades
Total Institutional Trades:	7,220
Avg Institutional Trade:	$2.83M
Avg Institutional Trade (30 D):	$3.25M
Avg Institutional Trade (90 D):	$3.35M
Avg Institutional Trade Volume:	.05M
Avg Institutional Trades (Per Day):	2

Market Closing Trades
Avg Closing Trade:	$4.59M
Avg Closing Trade (30 D):	$7.69M
Avg Closing Trade (90 D):	$7.73M
Avg Closing Volume:	87.57K

News

Feb 19, 2026 @ 4:00 PM Portnoy Law Firm Announces Class Action on Behalf ... Source: Portnoy Law Firm

Feb 19, 2026 @ 3:15 AM Ultragenyx Shareholder Alert: ClaimsFiler Reminds ... Source: Claimsfiler

Feb 18, 2026 @ 8:55 PM ROSEN, A RANKED AND LEADING LAW FIRM, Encourages U... Source: Rosen Law Firm

Feb 18, 2026 @ 5:00 PM Bronstein, Gewirtz & Grossman LLC Urges Ultragenyx... Source: Bronstein, Gewirtz & Grossman Llc

Feb 18, 2026 @ 12:06 AM CLASS ACTION ALERTS: Bragar Eagel & Squire, P.C. R... Source: Bragar Eagel & Squire, P.C.

Financials
	TTM	Q4 2025	FY 2025
Basic EPS	$-5.83	$-1.28	$-5.83
Diluted EPS	$-5.83	$-1.28	$-5.83
Revenue	$673M	$207.28M	$673M
Gross Profit
Net Income / Loss	$-575M	$-128.56M	$-575M
Operating Income / Loss	$-535M	$-113.28M	$-535M
Cost of Revenue
Net Cash Flow	$248M	$222.12M	$248M
PE Ratio

Splits
Jan 17, 2014	15:47